PDCD1 and melanoma: Recently, blocking the immunological checkpoints mediated by PD-1 or its ligands have led to significant clinical responses in patients with different types of cancers, such as melanoma (Ribas et al., 2015) and non-small cell lung cancer (Brahmer et al., 2015).